Illumina, Inc. Files 2023 Annual Report on Form 10-K
Ticker: ILMN · Form: 10-K · Filed: Feb 16, 2024 · CIK: 1110803
| Field | Detail |
|---|---|
| Company | Illumina, INC. (ILMN) |
| Form Type | 10-K |
| Filed Date | Feb 16, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 17 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, Annual Report, Illumina, Financials, Genomics
TL;DR
<b>Illumina, Inc. has filed its 2023 10-K report detailing financial performance and business operations.</b>
AI Summary
ILLUMINA, INC. (ILMN) filed a Annual Report (10-K) with the SEC on February 16, 2024. Illumina, Inc. filed its 2023 Form 10-K on February 16, 2024, reporting on the fiscal year ending December 31, 2023. The filing covers the company's financial performance and business operations for the fiscal year 2023. Key financial data and disclosures for the period are included in the report. The report details the company's product and service segments. Illumina, Inc. is incorporated in Delaware and headquartered in San Diego, CA.
Why It Matters
For investors and stakeholders tracking ILLUMINA, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Illumina's financial health and strategic direction for the past fiscal year, crucial for investors assessing its market position. The detailed segment information on products and services will help stakeholders understand revenue drivers and operational focus areas.
Risk Assessment
Risk Level: medium — ILLUMINA, INC. shows moderate risk based on this filing. The company's 10-K filing indicates a need for detailed financial disclosures, which can sometimes highlight areas of concern or complexity that warrant investor attention.
Analyst Insight
Investors should review the detailed financial statements and risk factors in the 10-K to understand Illumina's performance and outlook.
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Product | ||
| Service |
Key Numbers
- 2023-12-31 — Fiscal Year End (Reporting period)
- 2024-02-16 — Filing Date (Date of submission)
- 3826 — SIC Code (Standard Industrial Classification)
Key Players & Entities
- ILLUMINA, INC. (company) — Filer name
- ILMN (company) — Ticker symbol
- 2023-12-31 (date) — Fiscal year end
- 2024-02-16 (date) — Filing date
- San Diego, CA (location) — Business address
FAQ
When did ILLUMINA, INC. file this 10-K?
ILLUMINA, INC. filed this Annual Report (10-K) with the SEC on February 16, 2024.
What is a 10-K filing?
A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by ILLUMINA, INC. (ILMN).
Where can I read the original 10-K filing from ILLUMINA, INC.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ILLUMINA, INC..
What are the key takeaways from ILLUMINA, INC.'s 10-K?
ILLUMINA, INC. filed this 10-K on February 16, 2024. Key takeaways: Illumina, Inc. filed its 2023 Form 10-K on February 16, 2024, reporting on the fiscal year ending December 31, 2023.. The filing covers the company's financial performance and business operations for the fiscal year 2023.. Key financial data and disclosures for the period are included in the report..
Is ILLUMINA, INC. a risky investment based on this filing?
Based on this 10-K, ILLUMINA, INC. presents a moderate-risk profile. The company's 10-K filing indicates a need for detailed financial disclosures, which can sometimes highlight areas of concern or complexity that warrant investor attention.
What should investors do after reading ILLUMINA, INC.'s 10-K?
Investors should review the detailed financial statements and risk factors in the 10-K to understand Illumina's performance and outlook. The overall sentiment from this filing is neutral.
How does ILLUMINA, INC. compare to its industry peers?
Illumina operates in the life sciences industry, specifically in the field of genomic sequencing and array technologies.
Are there regulatory concerns for ILLUMINA, INC.?
The filing is a standard 10-K report under the Securities Exchange Act of 1934, requiring public companies to provide detailed financial and operational information annually.
Industry Context
Illumina operates in the life sciences industry, specifically in the field of genomic sequencing and array technologies.
Regulatory Implications
The filing is a standard 10-K report under the Securities Exchange Act of 1934, requiring public companies to provide detailed financial and operational information annually.
What Investors Should Do
- Analyze the detailed financial statements and management's discussion and analysis (MD&A) within the 10-K.
- Review the risk factors section to understand potential challenges and uncertainties facing Illumina.
- Compare key financial metrics and segment performance against previous years and industry benchmarks.
Key Dates
- 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
- 2024-02-16: Filing Date — Date the 10-K was officially filed with the SEC.
Year-Over-Year Comparison
This filing represents the annual 10-K for the fiscal year 2023, providing a comprehensive update compared to previous quarterly filings or the prior year's annual report.
Filing Stats: 4,358 words · 17 min read · ~15 pages · Grade level 17.7 · Accepted 2024-02-16 16:21:12
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value ILMN The Nasdaq Stock Market
Filing Documents
- ilmn-20231231.htm (10-K) — 2350KB
- fy2310-kex211subsidiariesq4.htm (EX-21.1) — 39KB
- ex231consentfy2310-kq4.htm (EX-23.1) — 3KB
- fy23q4ex311.htm (EX-31.1) — 15KB
- fy23q4ex312.htm (EX-31.2) — 14KB
- fy23q4ex321.htm (EX-32.1) — 7KB
- fy23q4ex322.htm (EX-32.2) — 7KB
- ex97compensationrecoverycl.htm (EX-97.0) — 38KB
- ilmn-20231231_g1.jpg (GRAPHIC) — 7KB
- ilmn-20231231_g2.gif (GRAPHIC) — 13KB
- ilmn-20231231_g3.jpg (GRAPHIC) — 2061KB
- ilmn-20231231_g4.jpg (GRAPHIC) — 103KB
- 0001110803-24-000010.txt ( ) — 18341KB
- ilmn-20231231.xsd (EX-101.SCH) — 86KB
- ilmn-20231231_cal.xml (EX-101.CAL) — 144KB
- ilmn-20231231_def.xml (EX-101.DEF) — 513KB
- ilmn-20231231_lab.xml (EX-101.LAB) — 1177KB
- ilmn-20231231_pre.xml (EX-101.PRE) — 814KB
- ilmn-20231231_htm.xml (XML) — 2108KB
Legal Proceedings
Legal Proceedings 29 Market Information 29 Share Repurchases and Sales 30 MANAGEMENT'S DISCUSSION & ANALYSIS Management's Overview and Outlook 31 Results of Operations 33 Liquidity and Capital Resources 37 Critical Accounting Policies and Estimates 39
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 43 Recent Accounting Pronouncements 45 CONSOLIDATED FINANCIAL STATEMENTS Index to Consolidated Financial Statements 46 Report of Independent Registered Public Accounting Firm 47 Consolidated Balance Sheets 50 Consolidated Statements of Operations 51 Consolidated Statements of Comprehensive (Loss) Income 52 Consolidated Statements of Stockholders' Equity 53 Consolidated Statements of Cash Flows 54
Notes to Consolidated Financial Statements
Notes to Consolidated Financial Statements 55 OTHER KEY INFORMATION
Controls and Procedures
Controls and Procedures 92 Adoptions, Modifications or Terminations of Trading Plans 94 Directors, Executive Officers and Corporate Governance 95
Executive Compensation
Executive Compensation 95
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 95 Certain Relationships and Related Transactions, and Director Independence 96 Principal Accountant Fees and Services 96 Exhibits, Financial Statement Schedules 96 Form 10-K Cross-Reference Index 101 1 Consideration Regarding Forward-Looking Statements This annual report on Form 10-K contains, and our officers and representatives may from time to time make, "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "continue," "project," "estimate," "expect," "strategy," "future," "likely," "may," "potential," "predict," "should," "will," or similar words or phrases, or the negatives of these words, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward looking. Examples of forward-looking statements include, among others, statements we make regarding: our expectations as to our future financial performance, results of operations, or other operational results or metrics; the benefits that we expect will result from our business activities and certain transactions we have completed, or may complete, such as product introductions, increased revenue, decreased expenses, and avoided expenses and expenditures; our expectations of the effect on our financial condition of claims, litigation, contingent liabilities, and governmental investigations, proceedings, and regulations; our strategies or expectations for product development, market position, financial results, and reserves; our ability to successfully implement cost reduction plans in a timely manner and the possibility that costs associated with our cost reduction plans are greater than we anticipate; our expectations regarding the pending divestiture of GRAIL, LLC (f/k/a